HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Reviva Pharmaceuticals (NASDAQ:RVPH) and maintained a $20 price target on the stock.
December 26, 2023 | 11:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates a Buy rating on Reviva Pharmaceuticals with a $20 price target.
The reiteration of a Buy rating and the maintenance of a $20 price target by a reputable analyst could positively influence investor sentiment and potentially lead to a short-term increase in the stock price of Reviva Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100